Please ensure Javascript is enabled for purposes of website accessibility

Will Abbott Labs Hit New Highs After Earnings?

By Dan Caplinger - Apr 15, 2013 at 11:25AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company continues moving forward without its proprietary pharmaceutical segment.

On Wednesday, Abbott Labs (ABT -1.14%) will release its latest quarterly results. The key to making smart investment decisions on stocks reporting earnings is to anticipate how they'll do before they announce results, leaving you fully prepared to respond quickly to whatever inevitable surprises arise. That way, you'll be less likely to make an uninformed kneejerk reaction to news that turns out to be exactly the wrong move.

Abbott is only part of what it used to be, with the highly successful AbbVie (ABBV -0.17%) pharmaceutical giant having traded as an independent company for a full quarter now. Now on its own, Abbott is free to pursue its own path. Let's take an early look at what's been happening with Abbott Labs over the past quarter and what we're likely to see in its quarterly report.

Stats on Abbott Labs

Analyst EPS Estimate


Year-Ago EPS


Revenue Estimate

$5.42 billion

Year-Ago Revenue

$9.46 billion*

Earnings Beats in Past 4 Quarters


Sources: Yahoo! Finance, S&P Capital IQ. *Year-ago figures exclude certain one-time items but include sales and income now attributable to AbbVie.

Will Abbott Labs keep moving forward?
Analysts have been mixed in their views of Abbott over the past few months. They've reined in their estimates for the just-ended quarter by a nickel per share, but they've expanded their earnings call for the full year by the same amount. The stock has chosen the more positive outlook, rising more than 12% since early January.

Until recently, when investors thought of Abbott, they likely thought of Humira, the blockbuster drug that is now the main driver of revenue for AbbVie. But now, Abbott gets substantial portions of its revenue from several sources, including nutritional products, diagnostics, vascular products, and generic drugs.

Right out of the gate, Abbott found some success, getting FDA approval for its XIENCE Xpedition drug-eluting stent. The stent market could prove increasingly important for Abbott going forward, as its Absorb line of products moves through clinical trials. Boston Scientific (BSX -1.57%) has a competing product, its Synergy line, which looks like the only potential roadblock for Abbott to capture first-mover status in bioresorbable stents.

But the company isn't without rivals. In nutritionals, Abbott has a huge opportunity to get its share of emerging-market growth. But Pfizer's (PFE -0.29%) former nutritional segment was also a major player in emerging markets, and with Nestle having spent $12 billion to pick up the business from Pfizer, Abbott can count on Nestle to move aggressively to capture market share in China, India, and elsewhere around the world.

In Abbott's quarterly report, keep your eyes open for two things. First, with the company having chosen to recall its FreeStyle InsuLinx blood glucose meters just this morning, Abbott will hopefully provide information on the potential impact on the company's current-quarter and future results. Also, be on the lookout for word about whether Abbott might follow through on rumors concerning a potential buyout of Ache Labs, a major Brazilian privately held drug company. With the generics market in Brazil doing particularly well, Ache could be just the entry point Abbott needs to boost its growth prospects as an independent company.

Click here to add Abbott Labs to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Abbott Laboratories Stock Quote
Abbott Laboratories
$113.23 (-1.14%) $-1.30
Pfizer Inc. Stock Quote
Pfizer Inc.
$51.19 (-0.29%) $0.15
Boston Scientific Corporation Stock Quote
Boston Scientific Corporation
$40.67 (-1.57%) $0.65
AbbVie Inc. Stock Quote
AbbVie Inc.
$154.52 (-0.17%) $0.26

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.